Novavax Inc vs Vistra Corp — how do they compare? Novavax Inc trades at $7.89 (market cap $1.31B), while Vistra Corp trades at $147.31 (market cap $48.64B). The key difference: Vistra Corp is far larger — about 37.1× Novavax Inc's market cap, and Vistra Corp pays a 0.63% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.
| NVAX | VST | |
|---|---|---|
Market Cap | $1.31B | $48.64B |
Sector | Health | Technology |
52-Week High | $11.19 | $217.92 |
52-Week Low | $6.22 | $134.71 |
Enterprise Value | $889.30M | $70.58B |
Dividend Yield | — | 0.63% |
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $7.89, down 0.75% on the day, with a bullish technical signal despite mixed indicators. The company reported a strong Q2 2026 earnings beat, raising its full-year revenue outlook, while maintaining a low valuation with a P/E of 3.14 and EV/EBITDA of 1.72. However, negative net income margin and shareholder equity highlight financial challenges.
The outlook is cautiously optimistic, driven by partnership milestones with Sanofi and cost reductions, but risks include persistent cash burn and competitive vaccine market pressures. Analyst consensus leans bullish with 74% buy ratings, suggesting potential upside if execution improves.
VST trades at $147.54, up 3.27% today, with strong analyst support (90.9% buy ratings) and a $239.75 consensus price target suggesting 62% upside. Recent Q2 2026 earnings showed mixed results with an EPS miss but 30% EBITDA growth to $1.77 billion, driven by data center demand. Technical indicators are bearish with support at $141, while fundamentals show robust profitability (11.55% net margin) offset by high valuation multiples (P/E 24.44).
The outlook remains positive given Vistra's positioning in the AI-powered data center boom, though risks include ERCOT pricing volatility and hedging losses. With institutional ownership stable and dividend payments consistent, the stock offers growth exposure to electricity demand trends, but investors should monitor execution on 2026 guidance and competitive pressures in the utility sector.
Trailing returns across standard periods
Latest headlines on both assets
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →Vistra is a leading integrated retail electricity and power generation company that serves as a critical infrastructure provider for the digital economy. It operates a diversified portfolio of zero-carbon nuclear and renewable assets alongside a massive, flexible natural gas fleet, positioning it as an indispensable partner for energy-intensive AI data centers and industrial electrification.
Read more on VST →